PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33247801-11 2021 Idebenone decreased the striatal levels of the lipid peroxidation products and increased the expression of glutathione peroxidase-4 (GPx-4), which is primarily known for lipid peroxidation and ferroptosis. idebenone 0-9 glutathione peroxidase 4 Rattus norvegicus 107-131 33247801-11 2021 Idebenone decreased the striatal levels of the lipid peroxidation products and increased the expression of glutathione peroxidase-4 (GPx-4), which is primarily known for lipid peroxidation and ferroptosis. idebenone 0-9 glutathione peroxidase 4 Rattus norvegicus 133-138 31775023-0 2020 The ying and yang of idebenone: Not too little, not too much - cell death in NQO1 deficient cells and the mouse retina. idebenone 21-30 NAD(P)H dehydrogenase, quinone 1 Mus musculus 77-81 33628024-0 2021 Therapeutic Effect of Idebenone on Rats with Vascular Dementia via the MicroRNA-216a/RSK2/NF-kappaB Axis. idebenone 22-31 microRNA 216a Rattus norvegicus 71-84 33628024-11 2021 Idebenone treatment elevated miR-216a expression in hippocampus of rats, but the therapeutic effect of Idebenone was averted by lentivirus inhibition of miR-216a. idebenone 0-9 microRNA 216a Rattus norvegicus 29-37 33628024-11 2021 Idebenone treatment elevated miR-216a expression in hippocampus of rats, but the therapeutic effect of Idebenone was averted by lentivirus inhibition of miR-216a. idebenone 103-112 microRNA 216a Rattus norvegicus 153-161 33628024-13 2021 Overexpression of RSK2 annulled the therapeutic effect of Idebenone on VD rats by activating the IkappaBalpha/NF-kappaB axis. idebenone 58-67 NFKB inhibitor alpha Rattus norvegicus 97-109 33628024-14 2021 Conclusion: Idebenone inhibits the activation of RSK2/IkappaBalpha/NF-kappaB axis by increasing miR-216a, thus alleviating oxidative stress and neuroinflammation in VD rats. idebenone 12-21 NFKB inhibitor alpha Rattus norvegicus 54-66 33628024-14 2021 Conclusion: Idebenone inhibits the activation of RSK2/IkappaBalpha/NF-kappaB axis by increasing miR-216a, thus alleviating oxidative stress and neuroinflammation in VD rats. idebenone 12-21 microRNA 216a Rattus norvegicus 96-104 32716144-2 2021 Herein, supported by a proposed combination of 1 and quinone drug idebenone, we rationally designed novel 1 -based MTDLs targeting Abeta and oxidative pathways. idebenone 66-75 amyloid beta precursor protein Homo sapiens 131-136 32557012-0 2021 Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway. idebenone 0-9 apolipoprotein E Mus musculus 46-62 32557012-0 2021 Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway. idebenone 0-9 sirtuin 3 Mus musculus 100-105 32557012-0 2021 Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway. idebenone 0-9 superoxide dismutase 2, mitochondrial Mus musculus 106-110 32557012-4 2021 In the present study, we aim to investigate weather idebenone protects against atherosclerosis in apolipoprotein E-deficient (apoE-/-) mice. idebenone 52-61 apolipoprotein E Mus musculus 126-130 32557012-5 2021 METHODS: apoE-/- mice receiving a high-fat diet (HFD) were treated with idebenone for 16 weeks. idebenone 72-81 apolipoprotein E Mus musculus 9-13 32557012-13 2021 In particular, the expression of SIRT3, SOD2, and NLRP3 was significantly regulated in the idebenone treatment groups compared with the HFD group both in vivo and in vitro. idebenone 91-100 sirtuin 3 Mus musculus 33-38 32557012-13 2021 In particular, the expression of SIRT3, SOD2, and NLRP3 was significantly regulated in the idebenone treatment groups compared with the HFD group both in vivo and in vitro. idebenone 91-100 superoxide dismutase 2, mitochondrial Mus musculus 40-44 32557012-13 2021 In particular, the expression of SIRT3, SOD2, and NLRP3 was significantly regulated in the idebenone treatment groups compared with the HFD group both in vivo and in vitro. idebenone 91-100 NLR family, pyrin domain containing 3 Mus musculus 50-55 32557012-15 2021 CONCLUSIONS: We demonstrated that idebenone acted as a mitochondrial protective agent by inhibiting the activation of NLPR3 via the SIRT3-SOD2-mtROS pathway. idebenone 34-43 sirtuin 3 Mus musculus 132-137 32557012-15 2021 CONCLUSIONS: We demonstrated that idebenone acted as a mitochondrial protective agent by inhibiting the activation of NLPR3 via the SIRT3-SOD2-mtROS pathway. idebenone 34-43 superoxide dismutase 2, mitochondrial Mus musculus 138-142 33045613-0 2020 Novel idebenone analogs block Shc"s access to insulin receptor to improve insulin sensitivity. idebenone 6-15 SHC adaptor protein 1 Homo sapiens 30-33 33045613-0 2020 Novel idebenone analogs block Shc"s access to insulin receptor to improve insulin sensitivity. idebenone 6-15 insulin receptor Homo sapiens 46-62 33045613-0 2020 Novel idebenone analogs block Shc"s access to insulin receptor to improve insulin sensitivity. idebenone 6-15 insulin Homo sapiens 46-53 33045613-4 2020 By high-throughput screening, idebenone was isolated as the first small molecule "Shc Blocker". idebenone 30-39 src homology 2 domain-containing transforming protein C1 Mus musculus 82-85 33045613-5 2020 Idebenone blocks p52Shc"s access to Insulin Receptor to increase insulin sensitivity. idebenone 0-9 insulin receptor Homo sapiens 36-52 33045613-5 2020 Idebenone blocks p52Shc"s access to Insulin Receptor to increase insulin sensitivity. idebenone 0-9 insulin Homo sapiens 65-72 33045613-6 2020 In this work the avidity of 34 novel idebenone analogs and 3 metabolites to bind p52Shc, and to block the interaction of p52Shc with the Insulin receptor was tested. idebenone 37-46 insulin receptor Homo sapiens 137-153 33045613-7 2020 Our hypothesis was that if an idebenone analog bound and blocked p52Shc"s access to insulin receptor better than idebenone, it should be a more effective insulin sensitizing agent than idebenone itself. idebenone 30-39 insulin receptor Homo sapiens 84-100 33045613-7 2020 Our hypothesis was that if an idebenone analog bound and blocked p52Shc"s access to insulin receptor better than idebenone, it should be a more effective insulin sensitizing agent than idebenone itself. idebenone 30-39 insulin Homo sapiens 84-91 33045613-9 2020 Of those 2 only idebenone analog #11 was a superior insulin sensitizer to idebenone. idebenone 16-25 insulin Homo sapiens 52-59 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 54-63 insulin Homo sapiens 23-30 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 54-63 insulin Homo sapiens 231-238 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 54-63 insulin Homo sapiens 231-238 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 23-30 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 231-238 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 231-238 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 23-30 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 231-238 33045613-10 2020 Also, the long-lasting insulin-sensitizing potency of idebenone in rodents over many hours had been puzzling, as the parent molecule degrades to metabolites within 1 h. We observed that two of the idebenone"s three metabolites are insulin sensitizing almost as potently as idebenone itself, explaining the persistent insulin sensitization of this rapidly metabolized molecule. idebenone 197-206 insulin Homo sapiens 231-238 32925607-0 2020 Idebenone protects mitochondrial function against amyloid beta toxicity in primary cultured cortical neurons. idebenone 0-9 amyloid beta precursor protein Homo sapiens 50-62 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 DNA-damage inducible transcript 3 Mus musculus 85-109 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 DNA-damage inducible transcript 3 Mus musculus 111-115 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 activating transcription factor 6 Mus musculus 118-151 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 activating transcription factor 6 Mus musculus 153-157 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 X-box binding protein 1 Mus musculus 163-186 32998266-7 2020 Furthermore, idebenone significantly reduced the expression of the ER stress markers C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6) and X-box binding protein-1 (XBP-1) at both mRNA and protein levels. idebenone 13-22 X-box binding protein 1 Mus musculus 188-193 32301145-7 2020 The study revealed that esculetin and idebenone significantly reduced the elevated levels of Bax/Bcl-2 ratio, malondialdehyde, and DNA fragmentation and increased total antioxidant capacity level in lenses compared to the cataract-induced group. idebenone 38-47 BCL2 associated X, apoptosis regulator Rattus norvegicus 93-96 32301145-7 2020 The study revealed that esculetin and idebenone significantly reduced the elevated levels of Bax/Bcl-2 ratio, malondialdehyde, and DNA fragmentation and increased total antioxidant capacity level in lenses compared to the cataract-induced group. idebenone 38-47 BCL2, apoptosis regulator Rattus norvegicus 97-102 32438202-0 2020 Idebenone attenuates cerebral inflammatory injury in ischemia and reperfusion via dampening NLRP3 inflammasome activity. idebenone 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 92-97 32438202-9 2020 Furthermore, idebenone treatment inhibited the process, thus suppressing the NLRP3-mediated inflammatory injury after OGD/R. idebenone 13-22 NLR family, pyrin domain containing 3 Rattus norvegicus 77-82 32438202-10 2020 In vivo, NLRP3 was activated in microglia of I/R rats and inhibition of NLRP3 was observed in idebenone treatment group, which had less neurological deficit and less infarct volume. idebenone 94-103 NLR family, pyrin domain containing 3 Rattus norvegicus 72-77 32438202-11 2020 INTERPRETATION: Our data revealed the anti-inflammatory effects of idebenone via suppressing activation of NLRP3 and ameliorating NLRP3-mediating damage in I/R, which may provide new insight in therapeutic strategy for ischemic stroke. idebenone 67-76 NLR family, pyrin domain containing 3 Rattus norvegicus 107-112 32438202-11 2020 INTERPRETATION: Our data revealed the anti-inflammatory effects of idebenone via suppressing activation of NLRP3 and ameliorating NLRP3-mediating damage in I/R, which may provide new insight in therapeutic strategy for ischemic stroke. idebenone 67-76 NLR family, pyrin domain containing 3 Rattus norvegicus 130-135 32350039-0 2020 Idebenone Has Distinct Effects on Mitochondrial Respiration in Cortical Astrocytes Compared to Cortical Neurons Due to Differential NQO1 Activity. idebenone 0-9 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 132-136 32350039-3 2020 NAD(P)H:quinone oxidoreductase 1 (NQO1) appears to be the main intracellular enzyme catalyzing idebenone reduction. idebenone 95-104 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 0-32 32350039-3 2020 NAD(P)H:quinone oxidoreductase 1 (NQO1) appears to be the main intracellular enzyme catalyzing idebenone reduction. idebenone 95-104 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 34-38 32350039-5 2020 Using primary rat cortical cells pooled from both sexes, we tested the hypotheses that the level of endogenous NQO1 activity limits the ability of neurons, but not astrocytes, to use idebenone as an electron donor to support mitochondrial respiration. idebenone 183-192 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 111-115 32350039-6 2020 We then tested the prediction that NQO1 induction by pharmacological activation of the transcription factor nuclear erythroid 2-related factor 2 (Nrf2) enables idebenone to bypass Complex I in cells with poor NQO1 expression. idebenone 160-169 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 35-39 32350039-6 2020 We then tested the prediction that NQO1 induction by pharmacological activation of the transcription factor nuclear erythroid 2-related factor 2 (Nrf2) enables idebenone to bypass Complex I in cells with poor NQO1 expression. idebenone 160-169 NFE2 like bZIP transcription factor 2 Rattus norvegicus 108-144 32350039-6 2020 We then tested the prediction that NQO1 induction by pharmacological activation of the transcription factor nuclear erythroid 2-related factor 2 (Nrf2) enables idebenone to bypass Complex I in cells with poor NQO1 expression. idebenone 160-169 NFE2 like bZIP transcription factor 2 Rattus norvegicus 146-150 32350039-8 2020 Importantly, idebenone supported mitochondrial oxygen consumption in the presence of a Complex I inhibitor in astrocytes but not neurons, and this ability was reversed by inhibiting NQO1. idebenone 13-22 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 182-186 32350039-11 2020 Carnosic acid-idebenone combination treatment promoted NQO1-dependent Complex I bypass activity in these cells. idebenone 14-23 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 55-59 32350039-12 2020 Thus, combination drug strategies targeting NQO1 may promote the repurposing of idebenone for additional disorders.SIGNIFICANCE STATEMENT Idebenone is used clinically to treat loss of visual acuity in Leber"s hereditary optic neuropathy. idebenone 138-147 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 44-48 32350039-16 2020 Our results suggest that idebenone behaves as an NQO1-dependent prodrug, raising the possibility that lack of neuronal NQO1 activity has contributed to the limited efficacy of idebenone in neurodegenerative disease treatment. idebenone 25-34 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 49-53 32350039-17 2020 Combination therapy with drugs able to safely induce NQO1 in neurons, as well as other brain cell types, may be able to unlock the neuroprotective therapeutic potential of idebenone or related quinones. idebenone 172-181 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 53-57 31775023-5 2020 A recent study suggested that the cytosolic enzyme NAD(P)H: quinone acceptor oxidoreductase (NQO1) is the major enzyme involved in the activation of idebenone, and the beneficial effects of idebenone are dependent on the expression of NQO1. idebenone 149-158 NAD(P)H quinone dehydrogenase 1 Homo sapiens 93-97 31775023-5 2020 A recent study suggested that the cytosolic enzyme NAD(P)H: quinone acceptor oxidoreductase (NQO1) is the major enzyme involved in the activation of idebenone, and the beneficial effects of idebenone are dependent on the expression of NQO1. idebenone 149-158 NAD(P)H quinone dehydrogenase 1 Homo sapiens 235-239 31775023-5 2020 A recent study suggested that the cytosolic enzyme NAD(P)H: quinone acceptor oxidoreductase (NQO1) is the major enzyme involved in the activation of idebenone, and the beneficial effects of idebenone are dependent on the expression of NQO1. idebenone 190-199 NAD(P)H quinone dehydrogenase 1 Homo sapiens 93-97 31775023-5 2020 A recent study suggested that the cytosolic enzyme NAD(P)H: quinone acceptor oxidoreductase (NQO1) is the major enzyme involved in the activation of idebenone, and the beneficial effects of idebenone are dependent on the expression of NQO1. idebenone 190-199 NAD(P)H quinone dehydrogenase 1 Homo sapiens 235-239 31775023-6 2020 Here, we confirm the NQO1-dependent activity of idebenone, but we also show, for the first time, that the cytotoxicity of idebenone is linked to cellular expression of NQO1. idebenone 48-57 NAD(P)H quinone dehydrogenase 1 Homo sapiens 21-25 31775023-6 2020 Here, we confirm the NQO1-dependent activity of idebenone, but we also show, for the first time, that the cytotoxicity of idebenone is linked to cellular expression of NQO1. idebenone 122-131 NAD(P)H quinone dehydrogenase 1 Homo sapiens 168-172 31775023-7 2020 Upon idebenone administration, cells deficient in NQO1 show a marked decrease in viability in comparison to NQO1 expressing cells, with idebenone causing ROS production and deleterious effects on ATP levels and cell viability. idebenone 5-14 NAD(P)H quinone dehydrogenase 1 Homo sapiens 50-54 31775023-7 2020 Upon idebenone administration, cells deficient in NQO1 show a marked decrease in viability in comparison to NQO1 expressing cells, with idebenone causing ROS production and deleterious effects on ATP levels and cell viability. idebenone 136-145 NAD(P)H quinone dehydrogenase 1 Homo sapiens 50-54 31775023-8 2020 In addition, our data highlights that only cells expressing NQO1 can significantly activate idebenone, indicating that other proposed metabolic activation pathways, such as complex II and glycerol-3-phosphate dehydrogenase, do not play a significant role in idebenone activation. idebenone 92-101 NAD(P)H quinone dehydrogenase 1 Homo sapiens 60-64 31775023-9 2020 Furthermore, we provide evidence of idebenone-induced toxicity in the retina ex-vivo, which can be explained by the variation of NQO1 expression between different cell types in the mouse retina. idebenone 36-45 NAD(P)H dehydrogenase, quinone 1 Mus musculus 129-133 31775023-12 2020 The specific dependence of idebenone activity on NQO1 may also explain the variation in patient outcomes in clinical trials. idebenone 27-36 NAD(P)H quinone dehydrogenase 1 Homo sapiens 49-53 31754474-9 2019 In vitro, treatment of LL29 cells with idebenone, but not CoQ10, suppressed TGF-beta-induced collagen production. idebenone 39-48 transforming growth factor beta 1 Homo sapiens 76-84 32243103-0 2020 Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy. idebenone 0-9 OPA1 mitochondrial dynamin like GTPase Homo sapiens 73-77 32243103-1 2020 We previously documented that idebenone treatment in OPA1-Dominant Optic Atrophy (OPA1-DOA) led to some degrees of visual improvement in seven patients. idebenone 30-39 OPA1 mitochondrial dynamin like GTPase Homo sapiens 53-57 32243103-1 2020 We previously documented that idebenone treatment in OPA1-Dominant Optic Atrophy (OPA1-DOA) led to some degrees of visual improvement in seven patients. idebenone 30-39 OPA1 mitochondrial dynamin like GTPase Homo sapiens 82-86 32243103-2 2020 We here present the results of a cohort study, which investigated the effect of off-label idebenone administration in a larger OPA1-DOA group compared with untreated patients. idebenone 90-99 OPA1 mitochondrial dynamin like GTPase Homo sapiens 127-131 31940911-7 2020 Consistent with its reported antioxidant function, idebenone significantly reduced the colonic levels of malondialdehyde (MDA) and nitric oxide (NO), and increased the expression of the redox factor NAD(P)H (nicotinamide adenine dinucleotide phosphate) dehydrogenase quinone-1 (NQO-1) in DSS-exposed mice. idebenone 51-60 NAD(P)H dehydrogenase, quinone 1 Mus musculus 278-283 31566908-7 2020 RESULTS: In MRL/lpr mice, idebenone-treated mice showed a significant reduction in mortality incidence (P < 0.01 versus untreated mice), and the treatment attenuated several disease features, including glomerular inflammation and fibrosis (each P < 0.05 versus untreated mice), and improved renal function in association with decreased renal expression of interleukin-17A (IL-17A) and mature IL-18. idebenone 26-35 interleukin 17A Mus musculus 356-371 31566908-7 2020 RESULTS: In MRL/lpr mice, idebenone-treated mice showed a significant reduction in mortality incidence (P < 0.01 versus untreated mice), and the treatment attenuated several disease features, including glomerular inflammation and fibrosis (each P < 0.05 versus untreated mice), and improved renal function in association with decreased renal expression of interleukin-17A (IL-17A) and mature IL-18. idebenone 26-35 interleukin 17A Mus musculus 373-379 31566908-7 2020 RESULTS: In MRL/lpr mice, idebenone-treated mice showed a significant reduction in mortality incidence (P < 0.01 versus untreated mice), and the treatment attenuated several disease features, including glomerular inflammation and fibrosis (each P < 0.05 versus untreated mice), and improved renal function in association with decreased renal expression of interleukin-17A (IL-17A) and mature IL-18. idebenone 26-35 interleukin 18 Mus musculus 392-397 31605306-6 2019 Patients with LHON may be prescribed ubiquinone (a component of RC3) or idebenone, a ubiquinone analogue with enhanced bioavailability to act downstream of RC1. idebenone 72-81 chromobox 8 Homo sapiens 156-159 30887496-2 2019 Idebenone is a potent antioxidant which has already been evaluated in several clinical trials in FRDA, with reports of symptomatic benefit but inconclusive objective results. idebenone 0-9 frataxin Homo sapiens 97-101 30290222-8 2018 Multiple assays of target engagement demonstrate that idebenone physically interacts with Shc protein. idebenone 54-63 SHC adaptor protein 1 Homo sapiens 90-93 30602587-6 2019 Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. idebenone 89-92 caspase 3 Homo sapiens 0-9 30602587-6 2019 Caspase-3 protein expression was also significantly decreased in U373MG cells indicating IDE-induced apoptosis that was confirmed by flow cytometric Annexin V/propidium iodide staining. idebenone 89-92 annexin A5 Homo sapiens 149-158 30290222-0 2018 Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. idebenone 0-9 insulin Homo sapiens 30-37 30290222-9 2018 Idebenone sensitizes mice to insulin in two different mouse models of prediabetes. idebenone 0-9 insulin Homo sapiens 29-36 30290222-0 2018 Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. idebenone 0-9 SHC adaptor protein 1 Homo sapiens 68-71 30290222-6 2018 Of the 7 drugs, idebenone dose-dependently bound Shc protein in the 50-100 nM range, and induced insulin sensitivity and cytoprotection in this same 100 nM range that clinically dosed idebenone reaches in human plasma. idebenone 16-25 SHC adaptor protein 1 Homo sapiens 49-52 30290222-6 2018 Of the 7 drugs, idebenone dose-dependently bound Shc protein in the 50-100 nM range, and induced insulin sensitivity and cytoprotection in this same 100 nM range that clinically dosed idebenone reaches in human plasma. idebenone 16-25 insulin Homo sapiens 97-104 30290222-10 2018 Genetic depletion of idebenone"s target eliminates idebenone"s ability to insulin-sensitize in vivo. idebenone 21-30 insulin Homo sapiens 74-81 30290222-10 2018 Genetic depletion of idebenone"s target eliminates idebenone"s ability to insulin-sensitize in vivo. idebenone 51-60 insulin Homo sapiens 74-81 30290222-11 2018 Thus, idebenone is the first-in-class member of a novel category of insulin-sensitizing and cytoprotective agents, the Shc inhibitors. idebenone 6-15 insulin Homo sapiens 68-75 30290222-11 2018 Thus, idebenone is the first-in-class member of a novel category of insulin-sensitizing and cytoprotective agents, the Shc inhibitors. idebenone 6-15 SHC adaptor protein 1 Homo sapiens 119-122 30290222-12 2018 Idebenone is an approved drug and could be considered for other indications such as type 2 diabetes and fatty liver disease, in which insulin resistance occurs. idebenone 0-9 insulin Homo sapiens 134-141 29857987-6 2018 RESULTS: Embryos from mild diabetic rats showed increased levels of nitrated proteins, 4-hydroxynonenal and matrix metalloproteinase 9, which were prevented by idebenone administration. idebenone 160-169 matrix metallopeptidase 9 Rattus norvegicus 108-134 29857987-7 2018 We also found a decreased embryonic expression of cytochrome c oxidase and reduced mRNA levels of peroxisome proliferator activated receptor-gamma coactivator-1-alpha and nuclear respiratory factor-1, both of which were prevented by idebenone administration to the diabetic pregnant rats. idebenone 233-242 nuclear respiratory factor 1 Rattus norvegicus 171-199 29694828-1 2018 Idebenone is a hydrophilic short-chain coenzyme (Co) Q analogue, which has been used as a potential bypass of defective complex I in both Leber Hereditary Optic Neuropathy and OPA1-dependent Dominant Optic Atrophy. idebenone 0-9 OPA1 mitochondrial dynamin like GTPase Danio rerio 176-180 27503028-0 2016 Idebenone Maintains Survival of Mutant Myocilin Cells by Inhibiting Apoptosis. idebenone 0-9 myocilin Homo sapiens 39-47 30171034-0 2018 Idebenone and coenzyme Q10 are novel PPARalpha/gamma ligands, with potential for treatment of fatty liver diseases. idebenone 0-9 peroxisome proliferator activated receptor alpha Homo sapiens 37-46 30171034-3 2018 A structural analog of coenzyme Q10 (idebenone) that elicits spatially restricted partial agonist activity for both PPARalpha and PPARgamma was identified. idebenone 37-46 peroxisome proliferator activated receptor alpha Homo sapiens 116-125 30171034-3 2018 A structural analog of coenzyme Q10 (idebenone) that elicits spatially restricted partial agonist activity for both PPARalpha and PPARgamma was identified. idebenone 37-46 peroxisome proliferator activated receptor gamma Homo sapiens 130-139 29552298-0 2018 Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. idebenone 53-62 lin-28 homolog A Homo sapiens 115-120 29552298-6 2018 Furthermore, idebenone and rasagiline induced the expression of Lin28A and Lin28B, respectively, which resulted in a reduced expression of microRNAs in the let-7 family and an increased protein output of Dicer. idebenone 13-22 lin-28 homolog A Homo sapiens 64-70 29552298-6 2018 Furthermore, idebenone and rasagiline induced the expression of Lin28A and Lin28B, respectively, which resulted in a reduced expression of microRNAs in the let-7 family and an increased protein output of Dicer. idebenone 13-22 lin-28 homolog B Homo sapiens 75-81 28643190-7 2017 In addition, we report novel idebenone properties in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers, while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation. idebenone 29-38 microtubule associated protein 2 Homo sapiens 173-177 28643190-7 2017 In addition, we report novel idebenone properties in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers, while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation. idebenone 29-38 glial fibrillary acidic protein Homo sapiens 192-196 28643190-7 2017 In addition, we report novel idebenone properties in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers, while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation. idebenone 29-38 microtubule associated protein 2 Homo sapiens 265-269 28648635-5 2017 Maternal treatments with idebenone, a mitochondrial antioxidant, led to reductions in all the pro-oxidant and pro-inflammatory markers evaluated and in PPARalpha protein expression in the heart of the offspring of diabetic rats. idebenone 25-34 peroxisome proliferator activated receptor alpha Rattus norvegicus 152-161 26820596-0 2016 A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function. idebenone 59-68 OPA1, mitochondrial dynamin like GTPase Mus musculus 89-93 26820596-6 2016 ATP levels were raised by 0.57 nmol/mg (97.73%, p=0.035) in brain from idebenone-treated Opa1 mutant mice, but in the liver there was an 80.35% (p=0.011) increase in oxidative damage. idebenone 71-80 OPA1, mitochondrial dynamin like GTPase Mus musculus 89-93 26820596-3 2016 We report a randomized, placebo-controlled trial of idebenone at 2000 mg/kg/day in 56 Opa1 mutant mice (B6;C3-Opa1(Q285STOP)), with RGC dendropathy and visual loss, and 63 wildtype mice. idebenone 52-61 OPA1, mitochondrial dynamin like GTPase Mus musculus 86-90 26196390-0 2015 Inhibition of ANO1/TMEM16A Chloride Channel by Idebenone and Its Cytotoxicity to Cancer Cell Lines. idebenone 47-56 anoctamin 1 Homo sapiens 14-18 26284974-0 2015 Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3beta/beta-catenin signalling pathways. idebenone 0-9 glycogen synthase kinase 3 beta Homo sapiens 128-136 26284974-0 2015 Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3beta/beta-catenin signalling pathways. idebenone 0-9 catenin beta 1 Homo sapiens 137-149 26284974-4 2015 The underlying mechanisms of idebenone included inhibition of oxidative damage, suppression of the down-regulation of Bcl-2 and up-regulation of Bax and cleaved caspase-3 in human umbilical vein endothelial cells (HUVECs) exposed to oxLDL. idebenone 29-38 BCL2 apoptosis regulator Homo sapiens 118-123 26284974-4 2015 The underlying mechanisms of idebenone included inhibition of oxidative damage, suppression of the down-regulation of Bcl-2 and up-regulation of Bax and cleaved caspase-3 in human umbilical vein endothelial cells (HUVECs) exposed to oxLDL. idebenone 29-38 BCL2 associated X, apoptosis regulator Homo sapiens 145-148 26284974-6 2015 Finally, pro-incubation with idebenone inhibited mitochondrial dysfunction induced by oxLDL through the mitochondrial-dependent apoptotic pathway and GSK3beta/beta-catenin signalling pathways. idebenone 29-38 glycogen synthase kinase 3 beta Homo sapiens 150-158 26284974-6 2015 Finally, pro-incubation with idebenone inhibited mitochondrial dysfunction induced by oxLDL through the mitochondrial-dependent apoptotic pathway and GSK3beta/beta-catenin signalling pathways. idebenone 29-38 catenin beta 1 Homo sapiens 159-171 26196390-0 2015 Inhibition of ANO1/TMEM16A Chloride Channel by Idebenone and Its Cytotoxicity to Cancer Cell Lines. idebenone 47-56 anoctamin 1 Homo sapiens 19-26 26196390-3 2015 As a result of the screening, idebenone, miconazole and plumbagin were identified as novel ANO1 inhibitors. idebenone 30-39 anoctamin 1 Homo sapiens 91-95 26196390-4 2015 Electrophysiological studies showed that idebenone, a synthetic analog of coenzyme Q10, completely blocked ANO1 activity in FRT cells expressing ANO1 without any effect on intracellular calcium signaling and CFTR, a cAMP-regulated chloride channel. idebenone 41-50 anoctamin 1 Homo sapiens 107-111 26196390-4 2015 Electrophysiological studies showed that idebenone, a synthetic analog of coenzyme Q10, completely blocked ANO1 activity in FRT cells expressing ANO1 without any effect on intracellular calcium signaling and CFTR, a cAMP-regulated chloride channel. idebenone 41-50 anoctamin 1 Homo sapiens 145-149 26196390-5 2015 The CaCC activities in PC-3 and CFPAC-1 cells expressing abundant endogenous ANO1 were strongly blocked by idebenone. idebenone 107-116 anoctamin 1 Homo sapiens 4-8 26196390-5 2015 The CaCC activities in PC-3 and CFPAC-1 cells expressing abundant endogenous ANO1 were strongly blocked by idebenone. idebenone 107-116 anoctamin 1 Homo sapiens 77-81 26196390-7 2015 These data suggest that idebenone, a novel ANO1 inhibitor, has potential for use in cancer therapy. idebenone 24-33 anoctamin 1 Homo sapiens 43-47 22965463-11 2012 A significant increase in caspase-3/7 activity was observed in cells treated with gentamicin or with idebenone + gentamicin (P = .005). idebenone 101-110 caspase 3 Homo sapiens 26-35 25262284-7 2015 Recently, cytoplasmic NAD(P)H: quinone oxidoreductase 1 (NQO1) was identified as a major enzyme catalyzing idebenone reduction. idebenone 107-116 NAD(P)H quinone dehydrogenase 1 Homo sapiens 22-55 25262284-7 2015 Recently, cytoplasmic NAD(P)H: quinone oxidoreductase 1 (NQO1) was identified as a major enzyme catalyzing idebenone reduction. idebenone 107-116 NAD(P)H quinone dehydrogenase 1 Homo sapiens 57-61 25262284-8 2015 While reduction allows idebenone to act as an antioxidant, evidence also suggests that NQO1 enables idebenone to shuttle reducing equivalents from cytoplasmic NAD(P)H to mitochondrial complex III, bypassing any upstream damage to the electron transport chain. idebenone 100-109 NAD(P)H quinone dehydrogenase 1 Homo sapiens 87-91 25262284-11 2015 As NQO1 is an inducible enzyme regulated by oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, optimizing NQO1 expression in appropriate cell types within a specific disease context may be key to delivering on idebenone"s therapeutic potential. idebenone 279-288 NAD(P)H quinone dehydrogenase 1 Homo sapiens 3-7 25262284-11 2015 As NQO1 is an inducible enzyme regulated by oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, optimizing NQO1 expression in appropriate cell types within a specific disease context may be key to delivering on idebenone"s therapeutic potential. idebenone 279-288 NFE2 like bZIP transcription factor 2 Homo sapiens 69-112 25262284-11 2015 As NQO1 is an inducible enzyme regulated by oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, optimizing NQO1 expression in appropriate cell types within a specific disease context may be key to delivering on idebenone"s therapeutic potential. idebenone 279-288 NFE2 like bZIP transcription factor 2 Homo sapiens 114-118 25262284-11 2015 As NQO1 is an inducible enzyme regulated by oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, optimizing NQO1 expression in appropriate cell types within a specific disease context may be key to delivering on idebenone"s therapeutic potential. idebenone 279-288 NAD(P)H quinone dehydrogenase 1 Homo sapiens 175-179 25421718-4 2015 The results from Western blotting in diabetic rats show that the upregulation of TJ-associated proteins occludin, and zonula occludens (ZO)-1 caused by the combination of insulin and idebenone is more remarkable than that with either agent alone. idebenone 183-192 occludin Rattus norvegicus 104-112 25421718-6 2015 These results suggest that the combination of insulin and idebenone could decrease the BBB permeability in diabetic rats by upregulating the expression of occludin, claudin-5, and ZO-1 and that the ROS/AGE/RAGE/NF-kappaB signal pathway might be involved in the process. idebenone 58-67 occludin Rattus norvegicus 155-163 25421718-6 2015 These results suggest that the combination of insulin and idebenone could decrease the BBB permeability in diabetic rats by upregulating the expression of occludin, claudin-5, and ZO-1 and that the ROS/AGE/RAGE/NF-kappaB signal pathway might be involved in the process. idebenone 58-67 claudin 5 Rattus norvegicus 165-174 25421718-6 2015 These results suggest that the combination of insulin and idebenone could decrease the BBB permeability in diabetic rats by upregulating the expression of occludin, claudin-5, and ZO-1 and that the ROS/AGE/RAGE/NF-kappaB signal pathway might be involved in the process. idebenone 58-67 tight junction protein 1 Rattus norvegicus 180-184 25421718-6 2015 These results suggest that the combination of insulin and idebenone could decrease the BBB permeability in diabetic rats by upregulating the expression of occludin, claudin-5, and ZO-1 and that the ROS/AGE/RAGE/NF-kappaB signal pathway might be involved in the process. idebenone 58-67 advanced glycosylation end product-specific receptor Rattus norvegicus 206-210 25684537-7 2015 Herein, we report administration of idebenone, a potent CoQ10 analogue, to the Ube3a(m-/p+) mouse model corrects motor coordination and anxiety levels, and also improves the expression of complexes III and IV in hippocampus CA1 and CA2 neurons and cerebellum in these Ube3a(m-/p+) mice. idebenone 36-45 ubiquitin protein ligase E3A Mus musculus 79-84 25684537-7 2015 Herein, we report administration of idebenone, a potent CoQ10 analogue, to the Ube3a(m-/p+) mouse model corrects motor coordination and anxiety levels, and also improves the expression of complexes III and IV in hippocampus CA1 and CA2 neurons and cerebellum in these Ube3a(m-/p+) mice. idebenone 36-45 carbonic anhydrase 1 Mus musculus 224-227 25684537-7 2015 Herein, we report administration of idebenone, a potent CoQ10 analogue, to the Ube3a(m-/p+) mouse model corrects motor coordination and anxiety levels, and also improves the expression of complexes III and IV in hippocampus CA1 and CA2 neurons and cerebellum in these Ube3a(m-/p+) mice. idebenone 36-45 carbonic anhydrase 2 Mus musculus 232-235 25684537-7 2015 Herein, we report administration of idebenone, a potent CoQ10 analogue, to the Ube3a(m-/p+) mouse model corrects motor coordination and anxiety levels, and also improves the expression of complexes III and IV in hippocampus CA1 and CA2 neurons and cerebellum in these Ube3a(m-/p+) mice. idebenone 36-45 ubiquitin protein ligase E3A Mus musculus 268-273 26044821-0 2015 Idebenone Prevents Oxidative Stress, Cell Death and Senescence of Retinal Pigment Epithelium Cells by Stabilizing BAX/Bcl-2 Ratio. idebenone 0-9 BCL2 associated X, apoptosis regulator Homo sapiens 114-117 26044821-0 2015 Idebenone Prevents Oxidative Stress, Cell Death and Senescence of Retinal Pigment Epithelium Cells by Stabilizing BAX/Bcl-2 Ratio. idebenone 0-9 BCL2 apoptosis regulator Homo sapiens 118-123 23668357-1 2014 OBJECTIVES: The objective of the study was to test the efficacy, safety and tolerability of triple therapy with deferiprone, idebenone and riboflavin in Friedreich"s ataxia (FRDA) patients in a clinical pilot study. idebenone 125-134 frataxin Homo sapiens 174-178 25929520-8 2015 Interestingly, when the cells from FRDA patients were co-cultured in the presence of idebenone and deferiprone, caspase expression decreased while antioxidant gene expression, as well as frataxin expression, increased. idebenone 85-94 frataxin Homo sapiens 35-39 25929520-8 2015 Interestingly, when the cells from FRDA patients were co-cultured in the presence of idebenone and deferiprone, caspase expression decreased while antioxidant gene expression, as well as frataxin expression, increased. idebenone 85-94 frataxin Homo sapiens 187-195 26044821-9 2015 The reduction of proapoptotic BAX and the elevation of antiapoptotic Bcl-2 under idebenone show that this process is rather mediated by inhibiting H2O2-induced apoptosis, not necrosis. idebenone 81-90 BCL2 apoptosis regulator Homo sapiens 69-74 26044821-10 2015 CONCLUSION: In this study, idebenone increased survival of ARPE-19 cells and reduced cell death, senescence, and oxidative stress by stabilizing the BAX/Bcl-2 ratio. idebenone 27-36 BCL2 associated X, apoptosis regulator Homo sapiens 149-152 26044821-10 2015 CONCLUSION: In this study, idebenone increased survival of ARPE-19 cells and reduced cell death, senescence, and oxidative stress by stabilizing the BAX/Bcl-2 ratio. idebenone 27-36 BCL2 apoptosis regulator Homo sapiens 153-158 23542074-0 2013 Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich"s ataxia. idebenone 16-25 frataxin Drosophila melanogaster 33-41 23661043-0 2013 Idebenone prevents human optic nerve head astrocytes from oxidative stress, apoptosis, and senescence by stabilizing BAX/Bcl-2 ratio. idebenone 0-9 BCL2 associated X, apoptosis regulator Homo sapiens 117-120 23661043-0 2013 Idebenone prevents human optic nerve head astrocytes from oxidative stress, apoptosis, and senescence by stabilizing BAX/Bcl-2 ratio. idebenone 0-9 BCL2 apoptosis regulator Homo sapiens 121-126 23661043-9 2013 In addition, idebenone pretreatment significantly attenuated the increase of histone-associated DNA fragmentation, induction of senescence-associated beta-galactosidase, and intracellular reactive oxygen species after treatment with H2O2. idebenone 13-22 galactosidase beta 1 Homo sapiens 150-168 23661043-10 2013 When ONHA cells were treated with idebenone and H2O2, real-time polymerase chain reaction and Western blot analysis yielded an increased expression of Bcl-2 and a decrease of BAX compared with those cells that were treated with H2O2 only. idebenone 34-43 BCL2 apoptosis regulator Homo sapiens 151-156 23661043-10 2013 When ONHA cells were treated with idebenone and H2O2, real-time polymerase chain reaction and Western blot analysis yielded an increased expression of Bcl-2 and a decrease of BAX compared with those cells that were treated with H2O2 only. idebenone 34-43 BCL2 associated X, apoptosis regulator Homo sapiens 175-178 23388408-0 2013 Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. idebenone 0-9 OPA1 mitochondrial dynamin like GTPase Homo sapiens 37-41 21547417-4 2011 In this study, we found that exposure of the dopaminergic neuroblastoma SHSY-5Y cells to 1-10 muM idebenone for 72 h had no effect on the cell viability revealed by trypan blue exclusion assay and MTT assay. idebenone 98-107 latexin Homo sapiens 94-97 22269948-3 2012 Two months later, the diagnosis of Leber hereditary optic neuropathy (LHON) 11778/ND4 was established and the patient was treated with 900 mg of idebenone daily. idebenone 145-154 mitochondrially encoded NADH dehydrogenase 4 Homo sapiens 82-85 21779958-1 2012 The aim of this study was to investigate the efficacy of idebenone on neurological function as assessed by ICARS and FARS neurological rating scales in pediatric Friedreich"s ataxia (FRDA) patients. idebenone 57-66 frataxin Homo sapiens 183-187 21779958-9 2012 The findings of the open-label IONIA-E study combined with the double-blind IONIA study indicate that idebenone at a dose of 1,350/2,250 mg/day may offer a therapeutic benefit to pediatric FRDA patients by stabilizing the overall neurological function and improving fine motor skills and speech. idebenone 102-111 frataxin Homo sapiens 189-193 21547417-5 2011 However, cells exposed to 25 muM or higher concentrations of idebenone showed extensive trypan blue-positive staining and significant reduction in cell viability revealed by MTT assay indicating that most of the cells were no longer viable. idebenone 61-70 latexin Homo sapiens 29-32 21547417-6 2011 Idebenone-induced cell death was characterized by genomic DNA fragmentation and accumulation of cytochrome c in the cytosol indicating that the death was apoptotic in nature. idebenone 0-9 cytochrome c, somatic Homo sapiens 96-108 21547417-7 2011 In addition, idebenone induced an increase in the total RNA of the pro-apoptosis protein BAX, it also increased the caspase-3 activity in the cell lysates when compared with the untreated control cells or cells exposed to 10 muM or lower concentrations of idebenone. idebenone 13-22 BCL2 associated X, apoptosis regulator Homo sapiens 89-92 21547417-7 2011 In addition, idebenone induced an increase in the total RNA of the pro-apoptosis protein BAX, it also increased the caspase-3 activity in the cell lysates when compared with the untreated control cells or cells exposed to 10 muM or lower concentrations of idebenone. idebenone 13-22 caspase 3 Homo sapiens 116-125 21547417-7 2011 In addition, idebenone induced an increase in the total RNA of the pro-apoptosis protein BAX, it also increased the caspase-3 activity in the cell lysates when compared with the untreated control cells or cells exposed to 10 muM or lower concentrations of idebenone. idebenone 13-22 latexin Homo sapiens 225-228 21547417-7 2011 In addition, idebenone induced an increase in the total RNA of the pro-apoptosis protein BAX, it also increased the caspase-3 activity in the cell lysates when compared with the untreated control cells or cells exposed to 10 muM or lower concentrations of idebenone. idebenone 256-265 BCL2 associated X, apoptosis regulator Homo sapiens 89-92 18784063-0 2009 Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. idebenone 55-64 fibroblast growth factor receptor substrate 2 Homo sapiens 46-49 21541760-0 2011 Idebenone inhibition of glutamate release from rat cerebral cortex nerve endings by suppression of voltage-dependent calcium influx and protein kinase A. idebenone 0-9 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 136-152 21483849-0 2011 NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. idebenone 32-41 NAD(P)H quinone dehydrogenase 1 Homo sapiens 0-4 21483849-4 2011 Using recombinant NAD(P)H:quinone oxidoreductase (NQO) enzymes, we observed that contrary to CoQ10 short-chain quinones such as idebenone are good substrates for both NQO1 and NQO2. idebenone 128-137 NAD(P)H quinone dehydrogenase 1 Homo sapiens 167-171 21483849-4 2011 Using recombinant NAD(P)H:quinone oxidoreductase (NQO) enzymes, we observed that contrary to CoQ10 short-chain quinones such as idebenone are good substrates for both NQO1 and NQO2. idebenone 128-137 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 176-180 22205977-0 2011 Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. idebenone 0-9 HtrA serine peptidase 2 Mus musculus 72-77 19775837-2 2009 In young FRDA children, some reports (based upon International Cooperative Ataxia Rating Scale scores (ICARS)) mention transient neurological improvement upon idebenone treatment. idebenone 159-168 frataxin Homo sapiens 9-13 19775837-5 2009 AIM: In young FRDA children, we aimed to determine longitudinal neurophysiological parameters during idebenone treatment. idebenone 101-110 frataxin Homo sapiens 14-18 19775837-10 2009 CONCLUSION: In FRDA children, age-related neurophysiological and ataxia parameters deteriorate during idebenone treatment. idebenone 102-111 frataxin Homo sapiens 15-19 19283347-0 2009 Idebenone: an emerging therapy for Friedreich ataxia. idebenone 0-9 frataxin Homo sapiens 35-52 19283347-1 2009 This paper reviews the history and pre-clinical development of idebenone and summarises the results of clinical studies, published from 1999 to 2008, on the use of idebenone in the treatment of patients with Friedreich ataxia (FRDA). idebenone 164-173 frataxin Homo sapiens 208-225 21541760-5 2011 The inhibitory effect of idebenone on evoked glutamate release was prevented by blocking the Ca(v)2.2 (N-type) and Ca(v)2.1 (P/Q-type) channels, but not by blocking intracellular Ca(2+) release or Na(+)/Ca(2+) exchange. idebenone 25-34 calcium voltage-gated channel subunit alpha1 A Rattus norvegicus 115-123 21541760-6 2011 Furthermore, the idebenone effect on 4-AP-evoked Ca(2+) influx and glutamate release was completely abolished by the protein kinase A (PKA) inhibitors, H89 and KT5720. idebenone 17-26 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 117-133 21541760-6 2011 Furthermore, the idebenone effect on 4-AP-evoked Ca(2+) influx and glutamate release was completely abolished by the protein kinase A (PKA) inhibitors, H89 and KT5720. idebenone 17-26 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 135-138 21541760-7 2011 On the basis of these results, it was concluded that idebenone inhibits glutamate release from rat cortical synaptosomes and this effect is linked to a decrease in [Ca(2+)](C) contributed by Ca(2+) entry through presynaptic voltage-dependent Ca(2+) channels and to the suppression of PKA signaling cascade. idebenone 53-62 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 284-287 21392622-2 2011 In this 6-month randomized, double-blind, controlled study, we sought to determine whether idebenone improves cardiac measures in FRDA. idebenone 91-100 frataxin Homo sapiens 130-134 21149629-8 2011 We found that idebenone functions as an inhibitor of voltage-gated potassium channels and thus likely mediates synergy through inhibition of the potassium fluxes which have been shown to be required for Nlrp1b inflammasome activation. idebenone 14-23 NLR family, pyrin domain containing 1B Mus musculus 203-209 20955109-5 2010 WHAT THE READER WILL GAIN: Following oral administration, idebenone is rapidly metabolized via oxidative shortening by a number CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) to yield QS10, QS8, QS6 and QS4. idebenone 58-67 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 144-150 20955109-5 2010 WHAT THE READER WILL GAIN: Following oral administration, idebenone is rapidly metabolized via oxidative shortening by a number CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) to yield QS10, QS8, QS6 and QS4. idebenone 58-67 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 152-158 20955109-5 2010 WHAT THE READER WILL GAIN: Following oral administration, idebenone is rapidly metabolized via oxidative shortening by a number CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) to yield QS10, QS8, QS6 and QS4. idebenone 58-67 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 160-167 20955109-5 2010 WHAT THE READER WILL GAIN: Following oral administration, idebenone is rapidly metabolized via oxidative shortening by a number CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) to yield QS10, QS8, QS6 and QS4. idebenone 58-67 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 169-175 20955109-5 2010 WHAT THE READER WILL GAIN: Following oral administration, idebenone is rapidly metabolized via oxidative shortening by a number CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) to yield QS10, QS8, QS6 and QS4. idebenone 58-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 180-186 18784063-0 2009 Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. idebenone 55-64 dystrophin, muscular dystrophy Mus musculus 72-82 18784063-7 2009 CONCLUSION: We have identified a novel potential therapeutic strategy for human DMD, as SNT-MC17/idebenone was cardioprotective and improved exercise performance in the dystrophin-deficient mdx mouse. idebenone 97-106 fibroblast growth factor receptor substrate 2 Homo sapiens 88-91 18784063-7 2009 CONCLUSION: We have identified a novel potential therapeutic strategy for human DMD, as SNT-MC17/idebenone was cardioprotective and improved exercise performance in the dystrophin-deficient mdx mouse. idebenone 97-106 dystrophin Homo sapiens 169-179 16866508-1 2006 The acyclic tetraphosphorus dication [Ph3P-PPh-PPh-PPh3]2+ has been formed by the reductive coupling of [Ph3P-PPhCl]+, providing a new synthetic method for the systematic development of catena-phosphorus cations. idebenone 186-192 enolase 1 Homo sapiens 43-46 17988688-3 2008 Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. idebenone 89-98 alpha glucosidase Homo sapiens 40-43 19096098-5 2008 Some short chain quinones are Complex I inhibitors (CoQ2, idebenone and its derivatives), while CoQ1, decylubiquinone~ (DB) and duroquinone (DQ) are good electron acceptors from Complex I. idebenone 58-67 decaprenyl diphosphate synthase subunit 1 Homo sapiens 96-100 18337669-13 2008 EPO-mRNA was markedly upregulated in the MMF-group and even more in the MMF/idebenone-group. idebenone 76-85 erythropoietin Rattus norvegicus 0-3 18337669-17 2008 Because ROS have the potential to suppress EPO expression, it can be hypothesized that enhanced EPO-mRNA expression in MMF/idebenone-treated rats is caused by antagonism of ROS. idebenone 123-132 erythropoietin Rattus norvegicus 43-46 18337669-17 2008 Because ROS have the potential to suppress EPO expression, it can be hypothesized that enhanced EPO-mRNA expression in MMF/idebenone-treated rats is caused by antagonism of ROS. idebenone 123-132 erythropoietin Rattus norvegicus 96-99 16866508-1 2006 The acyclic tetraphosphorus dication [Ph3P-PPh-PPh-PPh3]2+ has been formed by the reductive coupling of [Ph3P-PPhCl]+, providing a new synthetic method for the systematic development of catena-phosphorus cations. idebenone 186-192 enolase 1 Homo sapiens 47-50 15615771-4 2005 This has led to the use of antioxidants such as idebenone for FRDA therapy. idebenone 48-57 frataxin Homo sapiens 62-66 12949071-9 2003 These results indicate that dUb, like the clinically used ubiquinone analog idebenone, may serve as a candidate antioxidant compound for the development of pharmacological agents to treat diseases where there is an oxidative stress component. idebenone 76-85 subito Drosophila melanogaster 28-31 15028670-0 2004 Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. idebenone 0-9 frataxin Mus musculus 124-141 15028670-7 2004 Furthermore, we demonstrate that the antioxidant Idebenone delays the cardiac disease onset, progression and death of frataxin deficient animals by 1 week, but does not correct the Fe-S enzyme deficiency. idebenone 49-58 frataxin Mus musculus 118-126 11040339-0 2000 CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. idebenone 0-7 nerve growth factor Rattus norvegicus 68-87 11040339-6 2000 The effect of CV-2619 on H(2)O(2) exposure-induced cytotoxicity was blocked by cycloheximide and anti-NGF antibody. idebenone 14-21 nerve growth factor Rattus norvegicus 102-105 11040339-7 2000 The protective effect of CV-2619 was antagonized by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor 2"-amino-3"-methoxyflavone and the phosphatidylinositol-3 kinase inhibitor wortmannin. idebenone 25-32 Eph receptor B1 Rattus norvegicus 127-130 11040339-8 2000 These findings suggest that the effect of CV-2619 is mediated at least partly by NGF production in astrocytes and that ERK and phosphatidylinositol-3 kinases play a role in the downstream mechanism. idebenone 42-49 nerve growth factor Rattus norvegicus 81-84 10408810-4 1999 The observed inhibition by A beta of mitochondrial function and of glycolysis is blocked by the antioxidants vitamin E, idebenone, and GSH ethyl ester. idebenone 120-129 amyloid beta precursor protein Rattus norvegicus 27-33 10936587-2 2000 This study investigates in perfused pig livers the effect of the antioxidant idebenone and of cold ischemia time on the gene expression of c-fos and c-jun. idebenone 77-86 protein c-Fos Sus scrofa 139-144 10936587-2 2000 This study investigates in perfused pig livers the effect of the antioxidant idebenone and of cold ischemia time on the gene expression of c-fos and c-jun. idebenone 77-86 transcription factor Jun Sus scrofa 149-154 10936587-10 2000 C-fos and c-jun were strongly induced in livers stored for 20 h, which was attenuated by idebenone (p < 0.05). idebenone 89-98 protein c-Fos Sus scrofa 0-5 10936587-10 2000 C-fos and c-jun were strongly induced in livers stored for 20 h, which was attenuated by idebenone (p < 0.05). idebenone 89-98 transcription factor Jun Sus scrofa 10-15 9850939-6 1998 During the placebo controlled period (the first year of treatment), idebenone showed statistically significant dose-dependent improvement in the primary efficacy variable ADAS-Total and in all the secondary efficacy variables. idebenone 68-77 alkylglycerone phosphate synthase Homo sapiens 171-175 10221347-7 1999 We also verified that the ability to protect neurons in hypoxia and oxygen reperfusion was as follows: idebenone > insulin-like growth factor-1 (IGF-1) > nilvadipine. idebenone 103-112 insulin-like growth factor 1 Rattus norvegicus 118-146 10221347-10 1999 Furthermore, we surmise that idebenone, an antioxidant, decreases free radicals, and IGF-I attenuates p53-mediated apoptosis and thereby prevents cell death. idebenone 29-38 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 102-105 9987013-6 1999 Potent antioxidants idebenone and alpha-tocopherol prevented the behavioural deficits in Y-maze and water maze, but not passive avoidance, tasks in A beta-(1-42)-infused rats when they were repeatedly administered by mouth once a day from 3 days before the start of A beta infusion to the end of behavioural experiments. idebenone 20-29 amyloid beta precursor protein Rattus norvegicus 148-154 9987013-8 1999 These results suggest that treatment with antioxidants such as idebenone and alpha-tocopherol prevents learning and memory deficits caused by A beta. idebenone 63-72 amyloid beta precursor protein Rattus norvegicus 142-148 9267856-14 1997 Exploratory results for a subgroup of patients (ADAS-Total > or = 20) showed dose-related superiority of idebenone additionally on ADAS-Noncog and the CGI-Improvement scale. idebenone 105-114 alkylglycerone phosphate synthase Homo sapiens 48-52 9326418-9 1997 However, feeding the animals with idebenone over 7 days before explantation led to a faster recovery of ketone body ratio, paralleled by a substantial suppression of HSP70 expression. idebenone 34-43 heat shock 70 kDa protein 6 Sus scrofa 166-171 9267856-14 1997 Exploratory results for a subgroup of patients (ADAS-Total > or = 20) showed dose-related superiority of idebenone additionally on ADAS-Noncog and the CGI-Improvement scale. idebenone 105-114 alkylglycerone phosphate synthase Homo sapiens 131-135 7493000-0 1995 Effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) and related benzoquinones on porcine pancreas phospholipase A2 activity. idebenone 11-70 phospholipase A2 group IB Homo sapiens 129-145 7562397-7 1995 We demonstrate here that the oral administration of propentofylline, idebenone and trimethylquinone derivative, potent in vitro NGF synthesis stimulators, induced the increase in NGF protein and mRNA, and in choline acetyltransferase activity, in basal forebrain-lesioned and aged rats, but not in intact young rats. idebenone 69-78 nerve growth factor Rattus norvegicus 128-131 7562397-7 1995 We demonstrate here that the oral administration of propentofylline, idebenone and trimethylquinone derivative, potent in vitro NGF synthesis stimulators, induced the increase in NGF protein and mRNA, and in choline acetyltransferase activity, in basal forebrain-lesioned and aged rats, but not in intact young rats. idebenone 69-78 nerve growth factor Rattus norvegicus 179-182 7562397-7 1995 We demonstrate here that the oral administration of propentofylline, idebenone and trimethylquinone derivative, potent in vitro NGF synthesis stimulators, induced the increase in NGF protein and mRNA, and in choline acetyltransferase activity, in basal forebrain-lesioned and aged rats, but not in intact young rats. idebenone 69-78 choline O-acetyltransferase Rattus norvegicus 208-233 7493000-0 1995 Effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) and related benzoquinones on porcine pancreas phospholipase A2 activity. idebenone 72-81 phospholipase A2 group IB Homo sapiens 129-145 7493000-2 1995 Using dimyristoyl L-alpha-phosphatidylcholine (DMPC) as a substrate, the effects of idebenone and related benzoquinones on phospholipid digestion by phospholipase A2 (PLA2) was investigated. idebenone 84-93 phospholipase A2 group IB Homo sapiens 149-165 7493000-5 1995 It is suggested that the effect of idebenone on PLA2, in addition to its antioxidant activity lipid peroxidation, can be attributed to membrane-stabilizing activity. idebenone 35-44 phospholipase A2 group IB Homo sapiens 48-52 15374469-1 1990 The radical scavenging activity of oxidized and reduced idebenone (ID-O and ID-H, respectively) against superoxide radical (O2(-*) was studied in vitro using two methods: (1) O2(-*) radicals were generated enzymatically in a hypoxanthine (HPX)-xanthine oxidase (XOD) system and detected by 5,5-dimethyl-1-pyrroline N-oxide (DMPO) spin trapping. idebenone 56-65 indoleamine 2,3-dioxygenase 1 Homo sapiens 67-71 8058112-0 1994 Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. idebenone 23-32 nerve growth factor Rattus norvegicus 41-60 8058112-5 1994 We demonstrate here that the oral administration of idebenone, a potent in vitro nerve growth factors synthesis stimulator, induced an increase in nerve growth factor protein and mRNA, and in choline acetyltransferase activity, in basal forebrain lesioned rats, but not in intact rats. idebenone 52-61 nerve growth factor Rattus norvegicus 81-100 8058112-5 1994 We demonstrate here that the oral administration of idebenone, a potent in vitro nerve growth factors synthesis stimulator, induced an increase in nerve growth factor protein and mRNA, and in choline acetyltransferase activity, in basal forebrain lesioned rats, but not in intact rats. idebenone 52-61 choline O-acetyltransferase Rattus norvegicus 192-217 8058112-7 1994 These results suggest that idebenone stimulated nerve growth factor synthesis in vivo and ameliorates the behavioral deficits which were accompanied with the recovery of the reduced choline acetyltransferase activity in the basal forebrain-lesioned rats. idebenone 27-36 nerve growth factor Rattus norvegicus 48-67 8058112-7 1994 These results suggest that idebenone stimulated nerve growth factor synthesis in vivo and ameliorates the behavioral deficits which were accompanied with the recovery of the reduced choline acetyltransferase activity in the basal forebrain-lesioned rats. idebenone 27-36 choline O-acetyltransferase Rattus norvegicus 182-207 7511959-0 1994 Potentiation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptor function by a nootropic drug, idebenone. idebenone 140-149 glutamate receptor, ionotropic, AMPA2 (alpha 2) Mus musculus 16-109 7511959-1 1994 Effect of idebenone on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptor was evaluated using Xenopus oocytes injected with RNAs encoding mouse alpha 1 and alpha 2 AMPA receptors. idebenone 10-19 glutamate receptor, ionotropic, AMPA2 (alpha 2) Mus musculus 27-120 7926866-3 1994 We report here that repeated oral administration of the stimulators for the NGF synthesis, idebenone and propentofylline, produced a significant recovery of the reduced NGF content in the frontal and parietal cortices of aged rats. idebenone 91-100 nerve growth factor Rattus norvegicus 76-79 7926866-3 1994 We report here that repeated oral administration of the stimulators for the NGF synthesis, idebenone and propentofylline, produced a significant recovery of the reduced NGF content in the frontal and parietal cortices of aged rats. idebenone 91-100 nerve growth factor Rattus norvegicus 169-172 15374470-1 1990 Experiments have been performed using oxidized (ID-O) and reduced (ID-H) idebenone in various spin trapping systems. idebenone 73-82 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 67-71 15374479-8 1990 At these concentrations, idebenone induced a slight, but detectable, enhancement of the intracellular stress proteins, HSP70 and HSP90. idebenone 25-34 heat shock protein family A (Hsp70) member 4 Homo sapiens 119-124 15374479-8 1990 At these concentrations, idebenone induced a slight, but detectable, enhancement of the intracellular stress proteins, HSP70 and HSP90. idebenone 25-34 heat shock protein 90 alpha family class A member 1 Homo sapiens 129-134 15374469-1 1990 The radical scavenging activity of oxidized and reduced idebenone (ID-O and ID-H, respectively) against superoxide radical (O2(-*) was studied in vitro using two methods: (1) O2(-*) radicals were generated enzymatically in a hypoxanthine (HPX)-xanthine oxidase (XOD) system and detected by 5,5-dimethyl-1-pyrroline N-oxide (DMPO) spin trapping. idebenone 56-65 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 76-80 34571815-0 2021 Idebenone Decreases Abeta Pathology by Modulating RAGE/Caspase-3 Signaling and the Abeta Degradation Enzyme NEP in a Mouse Model of AD. idebenone 0-9 amyloid beta (A4) precursor protein Mus musculus 20-25 34369032-0 2021 Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice. idebenone 14-23 src homology 2 domain-containing transforming protein C1 Mus musculus 0-3 34369032-2 2021 Idebenone was recently identified as the first small-molecule Shc inhibitor drug. idebenone 0-9 src homology 2 domain-containing transforming protein C1 Mus musculus 62-65 34369032-4 2021 In the fibrotic MCD NASH model, idebenone reduced Shc expression and phosphorylation in peripheral blood mononuclear cells and Shc expression in the liver; decreased serum alanine aminotransferase and aspartate aminotransferase; and attenuated liver fibrosis as observed by quantitative polymerase chain reaction (qPCR) and hydroxyproline quantification. idebenone 32-41 src homology 2 domain-containing transforming protein C1 Mus musculus 50-53 34369032-4 2021 In the fibrotic MCD NASH model, idebenone reduced Shc expression and phosphorylation in peripheral blood mononuclear cells and Shc expression in the liver; decreased serum alanine aminotransferase and aspartate aminotransferase; and attenuated liver fibrosis as observed by quantitative polymerase chain reaction (qPCR) and hydroxyproline quantification. idebenone 32-41 src homology 2 domain-containing transforming protein C1 Mus musculus 127-130 34606154-6 2021 Antioxidants (N-acetylcysteine, idebenone, resveratrol, edaravone) improved alpha-glucosidase activity in rhGAA-treated cells, enhanced enzyme processing, and improved mannose-6-phosphate receptor localization. idebenone 32-41 sucrase-isomaltase Homo sapiens 76-93 34571815-0 2021 Idebenone Decreases Abeta Pathology by Modulating RAGE/Caspase-3 Signaling and the Abeta Degradation Enzyme NEP in a Mouse Model of AD. idebenone 0-9 advanced glycosylation end product-specific receptor Mus musculus 50-54 34571815-0 2021 Idebenone Decreases Abeta Pathology by Modulating RAGE/Caspase-3 Signaling and the Abeta Degradation Enzyme NEP in a Mouse Model of AD. idebenone 0-9 caspase 3 Mus musculus 55-64 34571815-0 2021 Idebenone Decreases Abeta Pathology by Modulating RAGE/Caspase-3 Signaling and the Abeta Degradation Enzyme NEP in a Mouse Model of AD. idebenone 0-9 amyloid beta (A4) precursor protein Mus musculus 83-88 34571815-0 2021 Idebenone Decreases Abeta Pathology by Modulating RAGE/Caspase-3 Signaling and the Abeta Degradation Enzyme NEP in a Mouse Model of AD. idebenone 0-9 tensin 2 Mus musculus 108-111 34571815-4 2021 Idebenone significantly downregulated Abeta plaque number via multi-directional pathways in this model. idebenone 0-9 amyloid beta (A4) precursor protein Mus musculus 38-43 34571815-5 2021 Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the Abeta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. idebenone 14-23 advanced glycosylation end product-specific receptor Mus musculus 36-40 34571815-5 2021 Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the Abeta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. idebenone 14-23 caspase 3 Mus musculus 41-50 34571815-5 2021 Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the Abeta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. idebenone 14-23 amyloid beta (A4) precursor protein Mus musculus 97-102 34571815-5 2021 Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the Abeta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. idebenone 14-23 tensin 2 Mus musculus 122-125 34571815-5 2021 Specifically, idebenone reduced the RAGE/caspase-3 signaling pathway and increased levels of the Abeta degradation enzyme NEP and alpha-secretase ADAM17 in 5xFAD mice. idebenone 14-23 a disintegrin and metallopeptidase domain 17 Mus musculus 146-152 34567221-0 2021 Idebenone-Activating Autophagic Degradation of alpha-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson"s Disease: A Network Pharmacological Approach. idebenone 0-9 synuclein alpha Homo sapiens 47-62 34567221-0 2021 Idebenone-Activating Autophagic Degradation of alpha-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson"s Disease: A Network Pharmacological Approach. idebenone 0-9 AKT serine/threonine kinase 1 Homo sapiens 81-84 34567221-0 2021 Idebenone-Activating Autophagic Degradation of alpha-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson"s Disease: A Network Pharmacological Approach. idebenone 0-9 mechanistic target of rapamycin kinase Homo sapiens 85-89 34567221-12 2021 In the cell model of PD, Idebenone activated autophagy and promoted alpha-synuclein degradation by suppressing the AKT/mTOR pathway. idebenone 25-34 mechanistic target of rapamycin kinase Homo sapiens 119-123 34567221-10 2021 The enrichment analysis highlighted manipulation of MAP kinase activity and the PI3K-AKT signaling pathway as potential pharmacological targets for Idebenone against PD. idebenone 148-157 AKT serine/threonine kinase 1 Homo sapiens 85-88 34567221-13 2021 Pretreating cells with chloroquine (CQ) to block autophagic flux could diminish the pharmacological effect of Idebenone to clear alpha-synuclein. idebenone 110-119 synuclein alpha Homo sapiens 129-144 34567221-11 2021 Additionally, molecular docking showed that AKT and MAPK could bind tightly with Idebenone. idebenone 81-90 AKT serine/threonine kinase 1 Homo sapiens 44-47 34567221-14 2021 Conclusion: This study demonstrated that Idebenone exerts its anti-PD effects by enhancing autophagy and clearance of alpha-synuclein, thus providing a theoretical and experimental basis for Idebenone therapy against PD. idebenone 41-50 synuclein alpha Homo sapiens 118-133 34567221-12 2021 In the cell model of PD, Idebenone activated autophagy and promoted alpha-synuclein degradation by suppressing the AKT/mTOR pathway. idebenone 25-34 synuclein alpha Homo sapiens 68-83 34567221-14 2021 Conclusion: This study demonstrated that Idebenone exerts its anti-PD effects by enhancing autophagy and clearance of alpha-synuclein, thus providing a theoretical and experimental basis for Idebenone therapy against PD. idebenone 191-200 synuclein alpha Homo sapiens 118-133 34567221-12 2021 In the cell model of PD, Idebenone activated autophagy and promoted alpha-synuclein degradation by suppressing the AKT/mTOR pathway. idebenone 25-34 AKT serine/threonine kinase 1 Homo sapiens 115-118 35014107-9 2022 Furthermore, IDB treatment increased the expression of GDF9 and BMP15 in IVM oocytes which attribute to improve the quality and outcome of IVM oocytes and the development competence of PA embryos in pigs. idebenone 13-16 growth differentiation factor 9 Sus scrofa 55-59 34175429-7 2021 The placentas of GDM rats showed a decrease in the mRNA levels of manganese superoxide dismutase and an increase in the production of nitric oxide, peroxynitrite-induced damage, and connective tissue growth factor levels, alterations that were prevented by the maternal Idebenone treatment in F0 rats. idebenone 270-279 superoxide dismutase 2 Rattus norvegicus 66-96 35014107-9 2022 Furthermore, IDB treatment increased the expression of GDF9 and BMP15 in IVM oocytes which attribute to improve the quality and outcome of IVM oocytes and the development competence of PA embryos in pigs. idebenone 13-16 bone morphogenetic protein 15 Sus scrofa 64-69 2569175-1 1989 The effects of idebenone and vinpocetine which reportedly prevent impairment of learning and memory were studied in vitro, on the long-term potentiation of the population spike in the pyramidal layer of CA3 region of slices of hippocampus in the guinea pig. idebenone 15-24 carbonic anhydrase 3 Cavia porcellus 203-206 35039479-7 2022 Our results showed that idebenone could reduce MPTP-induced dopaminergic neuron damage and improve movement disorders, memory, and learning ability, which may be associated with upregulating mitochondrial autophagy-related outer membrane proteins VDAC1 and BNIP3 and activating the Parkin/PINK1 mitochondrial autophagy pathway. idebenone 24-33 voltage-dependent anion channel 1 Mus musculus 247-252 35039479-7 2022 Our results showed that idebenone could reduce MPTP-induced dopaminergic neuron damage and improve movement disorders, memory, and learning ability, which may be associated with upregulating mitochondrial autophagy-related outer membrane proteins VDAC1 and BNIP3 and activating the Parkin/PINK1 mitochondrial autophagy pathway. idebenone 24-33 BCL2/adenovirus E1B interacting protein 3 Mus musculus 257-262 35039479-7 2022 Our results showed that idebenone could reduce MPTP-induced dopaminergic neuron damage and improve movement disorders, memory, and learning ability, which may be associated with upregulating mitochondrial autophagy-related outer membrane proteins VDAC1 and BNIP3 and activating the Parkin/PINK1 mitochondrial autophagy pathway. idebenone 24-33 PTEN induced putative kinase 1 Mus musculus 289-294 35039479-9 2022 In summary, our results confirm that idebenone can regulate the expression of the mitochondrial outer membrane proteins VDAC1 and BNIP3, activate Parkin/PINK1 mitophagy, promote the degradation of damaged mitochondria, reduce dopaminergic neuron damage, and improve behavioral disorders in Parkinson"s disease mice. idebenone 37-46 voltage-dependent anion channel 1 Mus musculus 120-125 35039479-9 2022 In summary, our results confirm that idebenone can regulate the expression of the mitochondrial outer membrane proteins VDAC1 and BNIP3, activate Parkin/PINK1 mitophagy, promote the degradation of damaged mitochondria, reduce dopaminergic neuron damage, and improve behavioral disorders in Parkinson"s disease mice. idebenone 37-46 BCL2/adenovirus E1B interacting protein 3 Mus musculus 130-135 35039479-9 2022 In summary, our results confirm that idebenone can regulate the expression of the mitochondrial outer membrane proteins VDAC1 and BNIP3, activate Parkin/PINK1 mitophagy, promote the degradation of damaged mitochondria, reduce dopaminergic neuron damage, and improve behavioral disorders in Parkinson"s disease mice. idebenone 37-46 PTEN induced putative kinase 1 Mus musculus 153-158 35222363-0 2022 Idebenone Regulates Abeta and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1beta Axis Activation. idebenone 0-9 amyloid beta (A4) precursor protein Mus musculus 20-25 35222363-0 2022 Idebenone Regulates Abeta and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1beta Axis Activation. idebenone 0-9 NLR family, pyrin domain containing 3 Mus musculus 100-105 35222363-0 2022 Idebenone Regulates Abeta and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1beta Axis Activation. idebenone 0-9 interleukin 1 alpha Mus musculus 119-127 35222363-3 2022 The present study explored the effects of idebenone on LPS- or Abeta-mediated neuroinflammation, learning and memory and the underlying molecular mechanisms in wild-type (WT) mice and 5xFAD mice, a mouse model of Alzheimer"s disease (AD). idebenone 42-51 amyloid beta (A4) precursor protein Mus musculus 63-68 35222363-4 2022 In male and female WT mice, idebenone upregulated neuroprotective NRF2 expression, rescued LPS-induced spatial and recognition memory impairments, and reduced NLRP3 priming and subsequent neuroinflammation. idebenone 28-37 nuclear factor, erythroid derived 2, like 2 Mus musculus 66-70 35222363-4 2022 In male and female WT mice, idebenone upregulated neuroprotective NRF2 expression, rescued LPS-induced spatial and recognition memory impairments, and reduced NLRP3 priming and subsequent neuroinflammation. idebenone 28-37 NLR family, pyrin domain containing 3 Mus musculus 159-164 35222363-5 2022 Moreover, idebenone downregulated LPS-mediated neurogliosis, reactive oxygen species (ROS) levels, and mitochondrial function in BV2 microglial cells and primary astrocytes by inhibiting NLRP3 inflammasome activation. idebenone 10-19 NLR family, pyrin domain containing 3 Mus musculus 187-192 35222363-6 2022 In 5xFAD mice, idebenone increased neuroprotective NRF2 expression and improved amyloid beta (Abeta)-induced cognitive dysfunction. idebenone 15-24 nuclear factor, erythroid derived 2, like 2 Mus musculus 51-55 35222363-6 2022 In 5xFAD mice, idebenone increased neuroprotective NRF2 expression and improved amyloid beta (Abeta)-induced cognitive dysfunction. idebenone 15-24 amyloid beta (A4) precursor protein Mus musculus 94-99 35222363-7 2022 Idebenone downregulated Abeta-mediated gliosis and proinflammatory cytokine levels in 5xFAD mice by modulating the vicious NLRP3/caspase-1/IL-1beta neuroinflammation cycle. idebenone 0-9 amyloid beta (A4) precursor protein Mus musculus 24-29 35222363-7 2022 Idebenone downregulated Abeta-mediated gliosis and proinflammatory cytokine levels in 5xFAD mice by modulating the vicious NLRP3/caspase-1/IL-1beta neuroinflammation cycle. idebenone 0-9 NLR family, pyrin domain containing 3 Mus musculus 123-128 35222363-7 2022 Idebenone downregulated Abeta-mediated gliosis and proinflammatory cytokine levels in 5xFAD mice by modulating the vicious NLRP3/caspase-1/IL-1beta neuroinflammation cycle. idebenone 0-9 caspase 1 Mus musculus 129-138 35222363-7 2022 Idebenone downregulated Abeta-mediated gliosis and proinflammatory cytokine levels in 5xFAD mice by modulating the vicious NLRP3/caspase-1/IL-1beta neuroinflammation cycle. idebenone 0-9 interleukin 1 alpha Mus musculus 139-147 35222363-8 2022 Taken together, our results suggest that idebenone targets neuroglial NLRP3 inflammasome activation and therefore may have neuroprotective effects and inhibit the pathological progression of neuroinflammation-related diseases. idebenone 41-50 NLR family, pyrin domain containing 3 Mus musculus 70-75 35593271-0 2022 Idebenone regulates sirt1/Nrf2/TNF-alpha pathway with inhibition of oxidative stress, inflammation, and apoptosis in testicular torsion/detorsion in juvenile rats. idebenone 0-9 sirtuin 1 Rattus norvegicus 20-25 35593271-0 2022 Idebenone regulates sirt1/Nrf2/TNF-alpha pathway with inhibition of oxidative stress, inflammation, and apoptosis in testicular torsion/detorsion in juvenile rats. idebenone 0-9 NFE2 like bZIP transcription factor 2 Rattus norvegicus 26-30 35593271-0 2022 Idebenone regulates sirt1/Nrf2/TNF-alpha pathway with inhibition of oxidative stress, inflammation, and apoptosis in testicular torsion/detorsion in juvenile rats. idebenone 0-9 tumor necrosis factor Rattus norvegicus 31-40 2569175-2 1989 Idebenone (10(-9) M-10(-6) M) or vinpocetine (10(-7) M-10(-6) M) significantly augmented long-term potentiation in the mossy fibre-CA3 pyramidal cell system, without any significant changes in population spikes in the absence of tetanic stimulation. idebenone 0-9 carbonic anhydrase 3 Cavia porcellus 131-134 2764647-3 1989 Significant increase in frequency in the alpha band (O1) and trends of increased appearance of beta waves, decreased appearance of alpha 1 bands, and lowered amplitude in the alpha 1 and alpha 2 bands were observed after administration of idebenone. idebenone 239-248 adrenoceptor alpha 1D Homo sapiens 131-138 2764647-3 1989 Significant increase in frequency in the alpha band (O1) and trends of increased appearance of beta waves, decreased appearance of alpha 1 bands, and lowered amplitude in the alpha 1 and alpha 2 bands were observed after administration of idebenone. idebenone 239-248 adrenoceptor alpha 1D Homo sapiens 175-194 2548448-2 1989 Idebenone inhibited the aggregation induced by collagen and thrombin in washed platelets, and by arachidonate and ADP in platelet-rich plasma (PRP). idebenone 0-9 coagulation factor II, thrombin Homo sapiens 60-68